30 September 2025 

GenIP Plc

("GenIP" or the "Company")

Half year results for the period ended 30 June 2025

GenIP Plc, a technology business providing Generative Artificial Intelligence (GenAI) services to help research organisations and corporations commercialise their innovations, is pleased to announce its unaudited results for the six months ended 30 June 2025.

Melissa Cruz, CEO of GenIP, commented:

"As a new company, established in February 2024 and listed on AIM within the last 12 months, the first post-IPO year is focussed on building the strategic and operational foundations to grow and scale.  With proven market demand and a service offering that was already delivering revenue at IPO we are well positioned to refine, develop, and expand that range to achieve growth, gain traction in the market and unlock shareholder value as we position for sustained growth.

GenIP's first half of 2025 has been a period of significant strategic progress, marked by international expansion, significant new client wins, and the launch of services shaped directly by market demand. We secured contracts across new markets including Saudi Arabia, Singapore, Brazil, and Chile, giving us a footprint in 25 countries globally. Our outstanding orderbook of $813k as of 30 June 2025 demonstrates both the scalability of our AI-powered model and the universality of the challenges we help clients solve. While these efforts have not yet been fully reflected in our financial results, we are confident that the second half of the year will be significantly stronger as we begin to convert our order book into recognised revenues and accelerate delivery of reports.

The momentum we are building is not just commercial but structural. Clients are turning to GenIP as an embedded partner, helping them prioritise complex portfolios, validate technologies against real market signals, and secure the talent required by new technologies to execute at pace. This reinforces our evolution from a project-based consultancy to an innovation platform, with repeatable, higher-margin workflows at its core.

Looking ahead, our priorities are clear: deepen program-level partnerships that drive recurring revenues, continue introducing client-led, high-margin services, and shift delivery toward SaaS-style engagements. At the same time, we are scaling the data assets that strengthen our competitive edge and unify our brand to create a seamless client journey.

We entered the second half of 2025 in a position of strength with $1,077k cash and cash equivalents, some of which will be used as cost of delivery for existing orders and enabling us to deliver on our strategic goals. Our growing pipeline, disciplined cost management, and expanding global footprint give us confidence in GenIP's ability to deliver sustained growth and long-term value creation for shareholders."

Business Highlights:

●     Won a $350,000 contract with a Saudi Arabian research organisation to deliver 400 GenAI-enhanced Invention Evaluator analytical assessments and technology commercialisation consulting services. We expect this order to be fulfilled during this financial year.

●     Secured a $65,000 contract with a Singapore-based research institute to deliver 100 GenAI-enhanced analytical assessments as part of its expansion into Asian markets through technology transfer sponsorships. We expect this order to be fulfilled during this financial year.

●     Launched a new AI-powered 'Competitive Intelligence Report' that analyses market landscapes, competitive positioning, and partnership/acquisition opportunities, with a Big Four accountancy firm as its first client using the service for strategic due diligence.

●     Secured our first Brazilian contract with a government research funding agency to provide AI-enhanced technology evaluation services for a national bio-energy initiative focused on commercialising sustainable energy innovations.

●     Sponsored and participated in the Association of University Technology Managers (AUTM) 2025 Annual Meeting to expand our network among 3,000+ global technology transfer professionals.

●     Expanded into the Republic of Chile through an engagement for 30 analytical assessment orders from a leading research institution.

●     Participated in the 2025 AUTM Canadian Region Meeting to introduce our GenAI analytics services to the Canadian technology transfer community and engage with potential clients, including universities and research institutions.

●     Headlined Knowledge Exchange UK 2025 with a closing keynote from our Chairman, Lord Willetts, on mission-driven knowledge exchange, providing a platform to connect with potential clients in the UK technology transfer industry.

Financial Highlights:

●     $1,077k cash and equivalents as of 30 June 2025

●     $813k total order book as of 30 June 2025

●     $488k orders received in H1 2025

●     $125k revenue in H1 2025

●     $572k operating loss in H1 2025

Post Period Highlights:

●     Secured our first Australian client for GenIP's Generative AI products through a government-funded consortium of universities and research organisations partnered with industry to advance technologies in advanced telecommunications, IoT connectivity, intelligent satellite systems, and next-generation Earth observation data services.

●     Forged a strategic partnership with 360 Social Impact Studios, a global innovation consulting firm and venture studio, and embedded GenIP's Invention Evaluator into their venture-building methodology.

●     Appointed as the official technology transfer services provider to the Chile-based GreenTech Innovation Platform as part of its strategic partnership with the Universidad Autónoma de Chile.

●     Launched the Invention Validator product line - Market Validation & Buyer Perception Studies - which goes beyond market sizing to test real-world adoption. These services design and run targeted questionnaires and stakeholder interviews to measure buyer interest, evaluate pricing sensitivity, and assess packaging and positioning, turning raw research into actionable market intelligence.

●     Strengthened our Talent Search business leadership with the appointment of Andrea Quiros to head Innovation & Deep Tech Talent. Andrea brings experience from IBM, Palo Alto Networks, and Amazon, and will establish scalable, data-driven recruitment solutions to help clients build the high-performing teams needed to execute commercialization strategies at pace.

●     Participated in the South African Research and Innovation Management Association (SARIMA) Annual Conference and engaged with leading African institutions on technology transfer and AI adoption, strengthening GenIP's collaboration opportunities across the African continent.

●     Participated in Campinas Innovation Week in Brazil, connecting with regional innovation ecosystems and expanding GenIP's presence in Latin America.

●     Hosted the first webinar in a new webinar series for Technology Transfer Offices and Officers, attracting more than 20 international participants from across the innovation and commercialization sector.

Outlook

GenIP expects to drive revenue growth through new product launches, increased order closures, and accelerated deliveries. Some of the larger orders secured in the early part of the year are scheduled for fulfilment by the end of the financial year, increasing second half revenues beyond that of the first half.

GenIP is advancing its strategy to accelerate growth, improve margins, and expand its global footprint. The priorities for the next phase of growth are:

●     Enhance revenue generation through an expanding product offering building on the entry level product range already in the market.

●     Expand program-level partnerships across universities, corporates, national agencies, and technology parks, with a clear objective to lift the corporate client share from ~30% to ~45% in the medium term.

●     Introduce high-margin, client-led services that build on the Invention Evaluator foundation, progressing delivery toward SaaS-style, dashboard-led engagements.

●     Scale automation and platform efficiencies to increase throughput from current levels while achieving and sustaining gross margins above 60%, supported by the expert human layer that ensures quality.

●     Leverage de-identified and aggregated portfolio data to refine AI models, deliver stronger decision support, and build a compounding data advantage.

●     Extend international reach across LATAM, Asia, and the Middle East through new partnerships and regional representatives, adding to the 25 countries where GenIP already operates.

For further information regarding GenIP, please visit www.genip.ai, or contact:

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

Notes to Editors

About GenIP

GenIP is a next-generation consultancy at the intersection of generative AI and innovation strategy. We empower corporates, venture funds, and research institutions to evaluate, commercialise, and scale breakthrough technologies. By combining proprietary GenAI algorithms with expert human analysis, GenIP delivers decision-grade insights and talent solutions that accelerate innovation outcomes.

Service Offerings

GenIP operates through two synergistic service lines:

Together, these services form a unified GenAI-enabled platform for innovation triage and execution.

Vision & Strategy

GenIP aims to become the global leader in generative AI analytics for innovation commercialisation. Our strategy is anchored in three growth pillars:

●     Organic Expansion
Scale Invention Evaluator and Recruitment Services through targeted outreach to corporates, VCs, and research institutions, supported by strategic marketing and digital engagement.

●     Service Deepening
Enhance functionality and margin by expanding GenAI capabilities across both service lines-unlocking new use cases and customer segments.

●     Strategic Acquisitions
Pursue bolt-on acquisitions of complementary GenAI services with validated market traction to broaden our offering and accelerate growth.

Forward looking statements

Certain statements contained in this announcement constitute forward-looking statements. When used in this announcement, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "seek", "propose", "estimate", "expect", and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial position, liquidity, prospects, growth, strategies and expectations of the industry in which the Company operates.

Such statements reflect the Company's current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to materially differ from those described in this announcement Should one or more of these risks or uncertainties materialise, or should assumptions underlying forward-looking statements prove incorrect, actual results may differ materially from those described in this announcement as "intended", "planned", "anticipated", "believed", "proposed", "estimated" or "expected".

For the avoidance of doubt, the contents of the Company's website and any hyperlinks accessible from the Company's website are not incorporated by reference into, and do not form part of, this announcement and investors should not rely on them.